Health · Medical Research · 2 hrs ago
Sellas says leukemia immunotherapy cut death risk in Phase 3 trial
Sellas Life Sciences said its experimental treatment succeeded in a Phase 3 trial for some patients with acute myeloid leukemia.
The treatment, called galinpepimut-S, is described as a blood cancer immunotherapy and cancer vaccine.
It reduced the risk of death by 41% compared with standard treatment, the company said.
The trial involved patients with advanced acute myeloid leukemia, a blood cancer.
The result met the trial’s main goal, according to Sellas.
The available information does not say what the company plans to do next.
Sellas Life Sciences said its experimental therapy galinpepimut-S reduced the risk of death by 41% compared with standard treatment in a Phase 3 trial.
The trial involved patients with advanced-stage acute myeloid leukemia, a blood cancer.
Sellas said the trial met its main goal.
The company described the result as a success in certain acute myeloid leukemia patients.
- Who
- Sellas Life Sciences reported the trial result.
- What
- Its experimental therapy galinpepimut-S reduced the risk of death by 41% compared with standard treatment, the company said.
- When
- Tuesday, Nov. 17, 2026.
- Where
- Not stated.
- Why
- The trial tested whether the therapy could improve survival for patients with acute myeloid leukemia.
This story does not have two clearly opposing sides.
Adam Feuerstein published a column predicting galinpepimut-S would not prolong survival in the Phase 3 study.
Sellas said the therapy met the trial’s main goal and reduced the risk of death by 41%.
- Therapy
- Galinpepimut-S, also called GPS
- Company
- Sellas Life Sciences
- Trial phase
- Phase 3
- Reported reduction in risk of death
- 41% compared with standard treatment
- Disease
- Acute myeloid leukemia
2 sources
What people are saying
It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.